Here, we combine multiplatform bulk and single-cell genomic analysis of somatic NF1-mutant, IDH wild-type glioblastomas with genome-wide CRISPRi screens and mouse intracranial tumor models to better understand the molecular landscape and MEK inhibitor responses in these tumors. The gene discussed is MAP2K7; the disease is glioblastoma.